(Q38025285)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22782008%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

The pathogenesis, diagnosis and treatment of Raynaud phenomenon (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22782008%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22782008%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Ariane L Herrick

series ordinal

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

10 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22782008%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22782008%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22782008%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22782008%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

469-479

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22782008%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrrheum.2012.96

7 February 2020

exact match

0 references

cites work

Prevalence of symptoms of Raynaud's phenomenon in general practice

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

The incidence and natural history of Raynaud's phenomenon in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Incidence and natural history of Raynaud phenomenon: A long-term follow-up (14 years) of a random sample from the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

The association of Raynaud's syndrome with rheumatoid arthritis--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Local thermal control of the human cutaneous circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Pathogenesis of Raynaud's phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Maximum blood flow and microvascular regulatory responses in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Blunted increase of digital skin vasomotion following acetylcholine and sodium nitroprusside iontophoresis in systemic sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Vascular disease in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Pathogenesis of systemic sclerosis: A vascular hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Macrovascular disease and systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

The pathology of scleroderma vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Vascular disease in scleroderma: mechanisms of vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Cellular and molecular aspects of vascular dysfunction in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Local ascorbate administration inhibits the adrenergic vasoconstrictor response to local cooling in the human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Platelet contributions to the pathogenesis of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Platelet-derived serotonin links vascular disease and tissue fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Familial aggregation of primary Raynaud's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Estrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Clinical practice. Raynaud's Phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Office capillaroscopy in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Assessing microvascular changes in systemic sclerosis diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Laser Doppler imaging: a developing technique for application in the rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Contemporary management of Raynaud's phenomenon and digital ischaemic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Selective and mixed endothelin receptor antagonism in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Surgery for ischemic pain and Raynaud's' phenomenon in scleroderma: a description of treatment protocol and evaluation of results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Long-term results of periarterial sympathectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Vascular remodeling: the role of angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Phosphodiesterase inhibitors in the management of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Management of vasospastic disorders with botulinum toxin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Botox therapy for ischemic digits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic scl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Sparing of the thumb in Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Variations of neuronal nitric oxide synthase in systemic sclerosis skin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Defective vasculogenesis in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Cooling evokes redistribution of alpha2C-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Hemorheologic profile in systemic sclerosis: Role ofNOS3 −786T>C and 894G>T polymorphisms in modulating both the hemorheologic parameters and the susceptibility to the disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

31 March 2020

12 December 2020

Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Pyroelectric vidicon thermography and cold challenge quantify the severity of Raynaud's phenomenon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Prazosin for Raynaud's phenomenon in progressive systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud's disease and Raynaud's phenomenon; studies on blood flow and clinical manifestations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.96

Pulmonary hypertension--beyond vasodilator therapy.

31 March 2020

1 reference

12 December 2020

Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison

1 reference

12 December 2020

Raynaud's phenomenon: a proposal for classification

1 reference

12 December 2020

Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers

1 reference

12 December 2020

Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study

1 reference

12 December 2020

Localization of endothelin-1 and its binding sites in scleroderma skin

1 reference

12 December 2020

Human postjunctional alpha-1 and alpha-2 adrenoceptors: differential distribution in arteries of the limbs

1 reference

12 December 2020

Raynaud's phenomenon (secondary).

1 reference

12 December 2020

Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon

1 reference

12 December 2020